The Fragility of Metaphors (FraMe): Learning, Loosing, and How to Train Them
Conditions: Schizophrenia; Psychosis Interventions: Behavioral: PragmaCom Sponsors: IRCCS San Raffaele Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
Conditions: Major Depressive Disorder; Obsessive-Compulsive Disorder; Schizophrenia; Generalized Anxiety Disorder; Mood Disorders; Psychiatric Disorder; Mental Disorder; Depression, Anxiety Interventions: Device: TMS Sponsors: Brigham and Women ' s Hospital; National Institutes of Health (NIH) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia
Conditions: Smoking Cessation Interventions: Drug: Naltrexone (Vivitrol); Drug: Bupropion Sponsors: The University of Texas Health Science Center, Houston Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion
Conditions: Mental Disorder; Schizophrenia; Major Depressive Disorder; Bipolar I Disorder Interventions: Drug: Placebo IEM tablet; Drug: Abilify MyCite ®; Device: D-Tect Patch Sponsors: Otsuka Pharmaceutical Development& Commercialization, Inc. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Ningbo Severe Mental Disorders Cohort
Conditions: Severe Mental Disorder; Schizophrenia; Bipolar Disorder; Schizo-Affective Psychosis; Paranoid Psychoses; Mental Retardation; Epileptic Psychosis Interventions: Other: Patient with severe mental disorder without intervention Sponsors: Ningbo University; The Affiliated Kangning Hospital of Ningbo University Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Theta-burst rTMS in schizophrenia to ameliorate negative and cognitive symptoms: study protocol for a double-blind, sham-controlled, randomized clinical trial
DiscussionThis is a double-blind, sham-controlled, randomized medical device study to assess the efficacy and safety of an augmented theta-burst rTMS treatment in schizophrenia. We hypothesize that social cognition and negative symptoms of patients on active therapy will improve significantly compared to patients on sham treatment.Trial registrationThe study protocol is registered at “ClinicalTrials.gov” with the following ID: NCT05100888. All items from the World Health Organization Trial Registration Data Set are registered. Initial release: 10/19/2021. (Source: Trials)
Source: Trials - April 17, 2024 Category: Research Source Type: clinical trials
Culture and Well-being: Art as Prescription Therapy ( " Art on Prescription " )
Conditions: Mental Health Issue; Anxiety Disorders; Depressive Disorder; Emotional Disorder; Schizophrenia; Autism Interventions: Other: Arts Sponsors: KAVADIA ELENI Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Reduction of Auditory-Verbal Hallucinations in Schizophrenia Through Cortical Neuromodulation
Conditions: Treatment Resistant Schizophrenia Interventions: Device: Active Transcranial Magnetic Stimulation (TMS); Device: Sham Transcranial Magnetic Stimulation (TMS) Sponsors: Centre Hospitalier St Anne Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
Sensory and Cognitive Predictions, and Their Disruptions in Schizophrenia
Conditions: Schizophrenia; Sensory Processing Disorder Interventions: Behavioral: Illusion task Sponsors: Centre Psychoth érapique de Nancy; Institut National de la Santé Et de la Recherche Médicale, France Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
A Clinical Trial to Evaluate Safety, Tolerance and Pharmacokinetics of JX11502MA Capsule in Patients With Schizophrenia.
Conditions: Schizophrenia Interventions: Drug: JX11502MA; Drug: Placebo Sponsors: Zhejiang Jingxin Pharmaceutical Co., Ltd.; Shanghai Mental Health Center Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
An Open-Label, Single Arm Study of the Efficacy of Accelerated Intermittent Theta Burst Stimulation in Schizophrenia Patients With Persistent Negative Symptoms
Conditions: Schizophrenia; Negative Type Interventions: Device: Accelerated iTBS Sponsors: Institute of Mental Health, Singapore Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2024 Category: Research Source Type: clinical trials
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
PRINCETON, N.J.--(BUSINESS WIRE) April 6, 2024 -- Bristol Myers Squibb (NYSE: BMY) today announced new interim results from the Phase 3 EMERGENT-4 open-label extension trial evaluating the long-term efficacy, safety and tolerability of KarXT... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 6, 2024 Category: Pharmaceuticals Source Type: clinical trials
Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
PRINCETON, N.J.--(BUSINESS WIRE) April 6, 2024 -- Bristol Myers Squibb (NYSE: BMY) today announced interim long-term safety, tolerability and metabolic outcomes data from its Phase 3 EMERGENT program evaluating KarXT (xanomeline-trospium) in adults... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 6, 2024 Category: Pharmaceuticals Source Type: clinical trials
Effect of tDCS on Inflammatory Biomarkers in Chronic Schizophrenia: A Randomised Double-Blind Controlled Trial.
Conditions: Aims to Compare the Effects of tDCS Verus Sham Stimulation on Inflammatory Markers IL-6 and TNF-alpha in Patients With Chronic Schizophrenia Interventions: Device: transcranial direct current stimulation Sponsors: All India Institute of Medical Sciences, Bhubaneswar Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
The Effect of Psychoeducation Focused on Reducing Internalized Stigma
Conditions: Schizophrenia; Treatment Adherence; Stigma, Social Interventions: Other: Psychoeducation Focused on Reducing Internalized Stigma Sponsors: Istanbul University - Cerrahpasa (IUC) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
